glp 1 china China's Hengrui/Kailera duo just filed an NDA for HRS9531: a dual GLP‑1/GIP agonist designed for long-term obesity treatment (not just diabetes). This strategy sets it apart from other GLP‑1 drugs. What makes China Opens Its Weight-Loss Drug
Pay in 4 interest-free payments of $5.44 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28

















![Delta Sleep-Inducing Peptide [DSIP] | 62568-57-4](https://www.biosynth.com/storage/BottleImages/PD/S4/BIOSYNTH_PDS-4054.png)








